What is the comparable dose of Vyvanse (lisdexamfetamine) to Adderall XR (amphetamine and dextroamphetamine) 15 mg in an adult patient with Attention Deficit Hyperactivity Disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dose Conversion: Adderall XR to Vyvanse

The comparable dose of Vyvanse to Adderall XR 15 mg is 30 mg, based on the approximate 2:1 conversion ratio between lisdexamfetamine and amphetamine salts.

Conversion Rationale

The conversion from Adderall XR to Vyvanse (lisdexamfetamine) follows a well-established pharmacokinetic principle: lisdexamfetamine is a prodrug that must be metabolized to d-amphetamine to become therapeutically active 1. This metabolic conversion results in approximately half the amount of active d-amphetamine compared to the parent compound by weight.

Standard Conversion Formula

  • Use a 2:1 ratio when converting from Adderall XR to Vyvanse - multiply the Adderall XR dose by 2 to determine the equivalent Vyvanse dose 1
  • For Adderall XR 15 mg, the equivalent Vyvanse dose is 30 mg once daily in the morning 2, 1
  • This conversion accounts for the fact that lisdexamfetamine must be enzymatically cleaved to release d-amphetamine, resulting in lower bioavailability of active drug per milligram 1

Pharmacokinetic Differences to Consider

While the 2:1 conversion provides a starting point, important pharmacokinetic differences exist between these formulations:

  • Vyvanse has a longer duration of action compared to Adderall XR, with efficacy demonstrated up to 12-13 hours post-dose, whereas Adderall XR typically provides 8-12 hours of coverage 1
  • Peak plasma concentrations occur later with Vyvanse (approximately 3.5 hours after oral administration) compared to Adderall XR (approximately 3 hours for the immediate-release component) 3, 1
  • The prodrug mechanism of lisdexamfetamine results in a smoother pharmacokinetic profile with less pronounced peaks and troughs 1

Titration After Conversion

After switching to Vyvanse 30 mg, monitor response and adjust as needed:

  • Allow at least one week at the initial converted dose before making adjustments to properly evaluate therapeutic response 4, 5
  • If symptom control is inadequate, increase in 10 mg increments weekly up to a maximum of 70 mg daily 1
  • The therapeutic dose range for adults typically falls between 30-70 mg daily 1

Critical Monitoring Parameters

When making this conversion, systematically assess:

  • ADHD symptom control using standardized rating scales (ADHD-RS or CAARS) at baseline and after one week 6, 7
  • Cardiovascular parameters including blood pressure and pulse at each visit 4, 6
  • Common adverse effects including decreased appetite, insomnia, headache, and irritability - these are typical of amphetamine products but may differ in intensity or timing with the prodrug formulation 1
  • Duration of symptom coverage throughout the day, as Vyvanse may provide longer afternoon/evening coverage than the previous Adderall XR regimen 1

Common Pitfalls to Avoid

  • Do not use a 1:1 conversion ratio - this will result in underdosing and inadequate symptom control 1
  • Avoid afternoon or evening dosing - administer Vyvanse upon awakening to minimize sleep disturbances, as the extended duration of action increases insomnia risk with late dosing 2, 1
  • Do not split or divide the capsule dose - Vyvanse capsules should be taken whole or the entire contents sprinkled on applesauce and consumed immediately 2
  • Do not assume immediate equivalence - individual response varies, and some patients may require dose adjustment above or below the calculated conversion dose 1

Special Considerations

  • Patients with active substance use disorder: Vyvanse has demonstrated lower abuse liability compared to immediate-release amphetamines due to its prodrug mechanism, making it a potentially safer option in this population 4, 8
  • Patients requiring extended daily coverage: The longer duration of action with Vyvanse may eliminate the need for afternoon supplementation that some patients require with Adderall XR 1

References

Related Questions

What is the recommended starting dose of Adderall XR (mixed amphetamine salts) for an adult with ADHD?
What are the recommended dosing guidelines, contraindications, common side effects, and monitoring recommendations for Adderall (mixed amphetamine salts) in adults and children?
What is the recommended starting dose of Adderall (mixed amphetamine salts) for an adult?
Is 50 or 60 mg of Adderall (amphetamine and dextroamphetamine) too much for an adult patient with Attention Deficit Hyperactivity Disorder (ADHD)?
For a 50‑year‑old woman with ADHD, is it appropriate to increase the dose of immediate‑release Adderall (mixed amphetamine salts)?
What is the recommended treatment for a patient with a sexually transmitted infection (STI), specifically chlamydia, using azithromycin (1gm)?
What is the role of N-acetylcysteine (NAC) in managing chronic obstructive pulmonary disease (COPD) in older adults, particularly those with a history of smoking or exposure to lung irritants and frequent exacerbations?
Can simultaneous use of Qelbree (viloxazine) and Adderall (amphetamine and dextroamphetamine) exacerbate side effects and increase stimulant intensity in an adult patient with attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), autism, generalized anxiety disorder, and social anxiety disorder?
Does viloxazine alter the blood levels of amphetamines in a patient with Attention Deficit Hyperactivity Disorder (ADHD) or depression who is already taking amphetamines?
Is shortness of breath a related symptom in an adult patient with a history of bifascicular block and possible pre-existing heart disease?
Are labs typically abnormal in patients with metastatic disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.